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Abstract
Background: Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor
receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted anti-HER2
therapies. However, recent analyses of clinical trial data have found evidence that HER2-targeted therapies may benefit a
sub-group of breast cancer patients with non-overexpressed HER2. This suggests that measurement of other biological
factors associated with HER2 cancer, such as HER2 signaling pathway activity, should be considered as an alternative
means of identifying patients eligible for HER2 therapies.
Methods: A new biosensor-based test (CELxTM HSF) that measures HER2 signaling activity in live cells is demonstrated
using a set of 19 human HER2+ and HER2– breast cancer reference cell lines and primary cell samples derived from two
fresh patient tumor specimens. Pathway signaling is elucidated by use of highly specific agonists and antagonists. The
test method relies upon well-established phenotypic, adhesion-related, impedance changes detected by the biosensor.
Results: The analytical sensitivity and analyte specificity of this method was demonstrated using ligands with high affinity
and specificity for HER1 and HER3. The HER2-driven signaling quantified ranged 50-fold between the lowest and highest
cell lines. The HER2+ cell lines were almost equally divided into high and low signaling test result groups, suggesting that
little correlation exists between HER2 protein expression and HER2 signaling level. Unexpectedly, the highest HER2-driven
signaling level recorded was with a HER2– cell line.
Conclusions: Measurement of HER2 signaling activity in the tumor cells of breast cancer patients is a feasible approach
to explore as a biomarker to identify HER2-driven cancers not currently diagnosable with genomic techniques. The wide
range of HER2-driven signaling levels measured suggests it may be possible to make a distinction between normal and
abnormal levels of activity. Analytical validation studies and clinical trials treating HER2- patients with abnormal HER2-
driven signaling would be required to evaluate the analytical and clinical validity of using this functional biomarker as a
diagnostic test to select patients for treatment with HER2 targeted therapy. In clinical practice, this method would require
patient specimens be delivered to and tested in a central lab.
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Background
Molecularly targeted therapies represent a major advance
in cancer treatment. Amongst the most consequential
therapies are those targeting human epidermal growth
factor receptor 2 (HER2). HER2 overexpression or gene
amplification is associated with more aggressive disease
progression, metastasis, and a poor clinical prognosis in
breast and gastric cancer [1, 2]. Current FDA-approved
treatments for HER2 overexpressed or gene amplified
(HER2+) breast cancers have significantly improved
clinical outcomes in the metastatic and adjuvant
settings and include small-molecule kinase inhibitors,
such as lapatinib (Tykerb), monoclonal antibodies,
such as trastuzumab (Herceptin) and pertuzumab
(Perjeta), and antibody-drug conjugates, such as ado-
trastuzumab emtansine (Kadcyla) [2, 3].
The conventional opinion that only patients with HER2
+ tumors benefit from HER2-targeted therapies has been
questioned by the review of results from several studies
and trials. While clinical trials conducted specifically to
evaluate the efficacy of different HER2 therapies in
HER2– patients have largely generated negative overall
results, some have suggested that a sub-group of HER2-
patients benefited. In one trial, estrogen receptor-positive
(ER+)/HER2- patients who entered the study with a
median of less than one month since discontinuation of
tamoxifen showed a statistically nonsignificant trend
toward improvement in both progression free survival and
clinical benefit rates that was nearly identical to that found
in a group of ER+/HER2+ patients [4]. In another trial
involving HER2- breast cancer patients, treatment with
lapatinib led to a statistically significant 27% downregula-
tion of Ki67 [5]. In this same trial, 14% of HER2-negative
patients showed a >50% reduction in Ki67 suggesting the
existence of a responding subset of the HER2– population.
Finally, re-analyses of previous trials indicate no signifi-
cant correlation exists between HER2 gene copy number
and trastuzumab benefit and that a sub-group of HER2-
breast cancer patients inadvertently included in a trial
intended for HER2+ patients benefited from HER2-
targeted therapies [6–9].
These results highlight the challenge of identifying a
targeted therapy benefit in HER2-breast cancer patients
when only a sub-group of 10–20% of them may be
responsive. No genomic-derived biomarker correlates for
this sub-group have been discovered. This suggests that
another biological factor associated with HER2 cancer,
dysfunctional HER2-driven signaling, may be a potential
diagnostic factor to consider as an alternative to mea-
surement of HER2 expression levels.
HER2 belongs to the human epidermal growth factor
receptor (HER) family of receptor tyrosine kinases, which
also includes HER1 (known as epidermal growth factor
receptor (EGFR)), HER3, and HER4. The HER family
members are expressed in many tissue types and play a key
role in cell proliferation and differentiation. The HER
receptors are generally activated by ligand binding leading
to the formation of homo and heterodimers followed by
phosphorylation of specific tyrosines in the cytoplasmic do-
main. In the HER family signaling system, EGF specifically
binds to EGFR, and NRG1b specifically binds to HER3 and
HER4. HER1 and HER4 are fully functional receptor
tyrosine kinases, whereas HER2 has no endogenous ligand
and HER3 has a weakly functional kinase domain. Due to
the absence of a specific ligand for HER2, HER2 primarily
functions as a ligand dependent heterodimer with other
members of the HER family [10]. The combination of re-
ceptor dimers influences subsequent signaling pathways.
For example, the HER1/HER2 heterodimer mainly activates
the Ras/MEK/ERK (MAPK), and PI3K/Akt signaling path-
ways [11]. Increasing evidence suggests that HER3 is the
preferred partner and to a somewhat lesser extent EGFR
and HER4 for amplified HER2 in breast cancer [12–14].
The HER2/HER3 heterodimer relies on HER3 for its signa-
ling, and HER3 can bind to p85 and strongly activate the
PI3K/Akt pathway [14, 15]. In addition, Hendriks et al. has
proposed that activation of ERK (MAPK) by HER2 arises
predominantly from HER1/HER2 heterodimers using their
study models [16]. Ligand binding triggers scaffolding for-
mation and downstream signaling cascades by recruitment
of specific substrate proteins [10]. Finally, other work has
demonstrated ~107 different states for HER1 that have very
rapid dynamics. Assuming that this accounting could be
applied to the other very similar receptors in the HER
family, this may explain why proteomic methods may be
unable to appropriately measure HER family-initiated sig-
naling dysfunction [17].
Label-free biosensor assays can provide real-time meas-
urement of cellular responses without the limitations of
standard endpoint assays. A biosensor is an analytical plat-
form that uses the specificity of a biological molecule or
cell along with a physicochemical transducer to convert a
biological response to a measureable optical or electrical
signal. A class of biosensor-based, label-free, whole-cell
screening assays offers an unprecedented combination of
label-free detection with sensitivity to live-cell responses
and has emerged as an useful tool in high-throughput
screening (HTS) for the discovery of new drugs over the
past years [18]. Label-free whole-cell assays offer a num-
ber of advantages. Most importantly, biosensors can dir-
ectly measure inherent morphological and adherent
characteristics of the cell as a physiologically or patho-
logically relevant and quantitative readout of cellular re-
sponse to signaling pathway perturbation. Numerous
research groups have demonstrated that biosensor-
based cell assays can quantitatively monitor dynamic
changes in cellular features such as cell adhesion and
morphology for complex endpoints that are modulated
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by many signal transduction pathways in live adherent
cells [19–21].
The potential of biosensor-based, label-free, whole-cell
assays to accurately identify pathway-driven disease and
reliably serve as clinical diagnostic tools remains to be
explored. The current work represents the first feasibility
assessment of viable cell signaling from cell lines and
primary cells in real time by applying a cell biosensor
assay methodology. The focus of this study is on the
HER2 signaling pathway in breast cancer using an
impedance whole-cell biosensor with well-established
reference breast cancer cell lines. Results for a feasible
and reliable biosensor-based label-free assay, the CELx
HER2 Signaling Function (HSF) test, are presented to
accurately determine whether live cells have abnormally
amplified HER2 pathway signaling activities and how the
pathway responds to HER2-targeted drugs in vitro. As a
proof-of-concept for potential clinical applications, the
test is applied to two patient tumor specimen-derived
primary cell samples ex vivo.
Methods
Chemicals and reagents
Recombinant human epidermal growth factor (EGF),
neuregulin 1b (NRG1b), and insulin like growth factor-1
(IGF-1) were purchased from R&D Systems (Minneapolis,
MN). Collagen was obtained from Advanced Biomatrix
(Carlsbad, CA) and fibronectin was obtained from Sigma
(St. Louis, MO). Lapatinib, afatinib, linsitinib, GSK1059615,
trametinib, doramapimod, and SP600125 were purchased
from SelleckChem (Houston, TX) and prepared at stock
concentrations in fresh 100% DMSO before final dilution
into assay medium. Pertuzumab was obtained from Kronan
Pharmacy (Uppsala, Sweden).
Cell culture
Human breast cancer cell lines used in this study
included SKBr3, BT474, BT483, T47D, MCF-7, AU565,
CAMA1, ZR75-1, ZR75-30, HCC202, HCC1428,
HCC1569, HCC1954, MDA-MB134vi, MDA-MB175vii,
MDA-MB231, MDA-MB361, MDA-MB415, MDA-
MB453 (all from ATCC, Manassas, VA), and EFM192A
(from Leibniz Institute DSMZ, Germany). All cell media
were from Mediatech (Manassas, VA) and fetal bovine
serum (FBS) was from Hyclone (Logan, UT). AU565,
ZR75-1, ZR75-30, HCC202, HCC1428, HCC1569,
HCC1954, and EFM192A were maintained in RPMI
1640 containing 10% FBS. T47D and BT483 were main-
tained in RPMI 1640 containing 10% FBS and 10ug/mL
human insulin (Mediatech, Manassas, VA). MDA-
MB134vi, MDA-MB175vii, MDA-MB231, MDA-MB361,
and MDA-MB453 were maintained in DMEM contain-
ing 10% FBS. MDA-MB415 was maintained in DMEM
containing 15% FBS, 10ug/mL human insulin, and 10ug/
mL glutathione (Sigma, St. Louis, MO). BT474 and
CAMA1 were maintained in EMEM containing 10%
FBS. MCF-7 was maintained in EMEM containing 10%
FBS and 10ug/mL human insulin. SKBr3 was maintained
in McCoy’s containing 10% FBS. The cell lines were
authenticated in March 2016, by ATCC, and results were
compared with the ATCC short-tandem repeat (STR)
database.
The use of excess surgically resected human breast can-
cer tissue in this study was received from the University of
Minnesota tissue procurement department (Minneapolis,
MN) and Capitol Biosciences tissue procurement services
(Rockville, MD). The material received was excess tissue
and de-identified. Liberty IRB (Columbia, MD) deter-
mined that this research does not involve human subjects
as defined under 45 CFR 46.102(f) and granted exemption
in written form. The data were analyzed and reported
anonymously. Patient specimens were received from the
clinic at 0–8 °C within 24 h from removal. Methods for
tissue extraction, primary cell culture, and short-term
population doublings are essentially as described previ-
ously [22, 23]. Briefly, 20–70 mg tissue was minced with
scalpels to <2 mm pieces and cryopreserved until testing
[24] or used fresh. Tissue (20–40 mg) for CELx HSF test-
ing was enzymatically disaggregated for minimal time to
obtain cells and cell clusters in collagenase and hyaluroni-
dase (Worthington Biochemical, Lakewood, NJ) at 37 °C
in 5% CO2. On the same day as digestion, the disaggre-
gated tissue was washed in culture media to remove disag-
gregation enzymes, plated on 6-well tissue culture plates
in serum-free mammary epithelial cell media, and grown
4–14 days until approximately 2 × 105 cells were available.
Trypan blue staining was used before initial plating to
determine the viability of each specimen.
Real-time assessment of HER2 signaling network activity
Experiments were performed using the xCELLigence
Real Time Cell Analyzer (RTCA) (ACEA Biosciences,
San Diego, CA), an impedance-based biosensor, which
was placed in a humidified incubator at 37 °C and 5%
CO2. Cells were seeded in triplicate in 96-well sensor
plates (pre-coated with collagen and fibronectin) in
serum-free minimal medium (assay medium) the day
before ligands were added. The impedance CI value
reflects the aggregate of cellular events that include the
viability of the cells, the relative density of cells over the
electrode surface, morphological changes, and the rela-
tive adherence of the cells. The adherence characteristic
is dependent on the type and concentration of adhesion
proteins on the cell surface and is regulated at least in
part by cellular signaling through cell-cell and cell-ECM
interactions. Automatic impedance recording began after
cell seeding and continued throughout the whole course
of an experiment, ending 6–10 h after growth factor
Huang et al. BMC Cancer  (2017) 17:199 Page 3 of 18
addition. The instrument software converts impedance
in ohms (Ω) into a cell index (CI) value by the algorithm
CI =Ω/15. In the case of drug/inhibitor pretreatment,
drugs/inhibitors were freshly prepared in assay medium
at 20× of working concentrations and added into the
sensor plates two hours prior to the addition of growth
factors.
To ensure dynamic pathway signaling related events
are the primary cell activity measured, and that the
effect of cell proliferation is excluded, only CI values col-
lected within 30 h of seeding were analyzed in the CELx
HSF test. This 30-h period includes the time just after
the cells are seeded onto the sensor up to the time point
6–10 h after growth factor addition. The signaling acti-
vity following growth factor addition is the only relevant
time period for the CELx test measurand as it corre-
sponds to the period when dynamic pathway signaling is
occurring in the cell sample.
In the CELx HSF test feasibility work described herein,
EGF or NRG1b stimulation was used in combination with
specific types of HER2 inhibitors to provide insights into
dimerization of HER2 related to CELx Test signals. Growth
factors were freshly prepared in the same assay medium at
10X of working concentrations and added 18–24 h after
cell seeding. The same volume of assay medium instead of
the growth factors/drugs/inhibitors was added in the
“blank”, media only wells (control wells). All additions were
performed with a VIAFLO automatic liquid handler (Inte-
gra Biosciences, Hudson, NH).
Two inhibitory molecules were selected that act by
directly binding the receptor and affecting signaling
initiation. Lapatinib is a small-molecule kinase inhibitor
that blocks receptor signaling processes by reversibly
binding to the ATP-binding pocket of the protein kinase
domain of HER family members, preventing receptor
phosphorylation and activation [25]. Pertuzumab is an
anti-HER2 mAb that inhibits dimerization of HER2 with
other receptors by binding to subdomain II of the HER2
protein and has been shown to interfere with HER2
signaling [26, 27].
Data analysis and statistics
CELx test data was exported from the RTCA software
file for the time versus Cell Index (CI) analysis by Trace-
Drawer (Ridgeview Instruments, Sweden) and Microsoft
Excel. The cell index versus time course data essentially
fell into one of 3 groups for each cell sample tested: cells
with addition of media only (C), cells with addition of
growth factor stimulus only (CF), and cells with addition
of an antagonist drug followed by a growth factor
stimulus (CDF). To permit inter-sample quantitative
comparison, the cell index was set to zero for each set of
CI versus time course data at the time point of stimulus
addition to a cell sample. After the stimulus was added,
data were assessed using the CI versus time data by one
of the following algorithms:
 For determining the magnitude of the stimulus,
CF-C was used.
 For determining the absolute amount of HER2
involvement in a particular stimulus in the CELx
HSF test, (CF-C)-(CDF-C) was used, combining the
EGF and NRG1b stimulus data to arrive at a
comparative total amount of HER2 signaling
response for a particular cell sample.
 Percentage of stimulus signal reduction by drug
inhibition was calculated by [1-[(CF-C)-(CDF-C)]/
(CF-C)]*100.
All dose–response curves were obtained using nonlinear
regression curve fitting with GraphPad Prism 6 (GraphPad
Software, La Jolla, CA). Pearson correlation analysis was
performed using GraphPad Prism 6 to evaluate the rela-
tionships among the variables of interest. P < 0.05 was
considered statistically significant.
Flow cytometry (fluorescence-activated cell marker
analysis)
Flow cytometric analysis of luminal (EpCAM+, Claudin4+)
and basal (CD49f+, CD10+) markers as well as estrogen
receptor (ER) and progesterone receptor (PR) was per-
formed on the primary samples to confirm epithelial cell
identity and that fibroblast content was low. Fluorescence
flow cytometry was also used to assess protein expression
levels of the cell lines and primary cells used in this study.
Antibodies used in this study are described in Additional
file 1: Table S1. Sample data was collected on a BD FACS-
Calibur (BD Biosciences, San Jose, CA) equipped with a
488-nm and 637-nm laser. Data were analyzed with
FlowJo 2 (FlowJo LLC, Ashland, OR).
Results
Basic principle of the CELx HER2 signaling function test
for real-time assessment of the HER2 signaling network
One of the first properties noted with the biosensor
performance was that absolute baseline attachment CI
values can be variable among different reference cell
lines derived from the same tissue type. This could be
influenced by cell morphology and the exact nature of
cell attachment. Cells from the same sample gave very
similar well-to-well CI values for baseline attachment.
We found no significant correlation between this
baseline attachment impedance and the magnitude of
the signaling response upon cell perturbations. Using
the human breast cancer BT474 cell line as an example,
a typical CI time-course curve of over approximately
100-h period after seeding onto the sensor plate is
shown, including quantitative measurement of initial cell
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attachment (~1CI, about ~200x background of 0.005CI),
reflecting the balance of settling, adhesion, spreading),
lag (plateau and stabilization), logarithmic growth (pro-
liferation), and formation of a cell (mono) layer (Fig. 1a).
Human breast tumor-derived primary cells displayed a
similar CI time-course curve and a representative curve of
patient R56 primary cells is shown in Fig. 1b. The initial
cell adhesion (<20 h, 3.8CI) CI is somewhat higher,
whereas the cell proliferation slope is similar compared to
other breast cancer cell lines; though the slope of cells
from different specimen can vary depending on the
disease state. These observations are consistent with
morphology differences (Fig. 1c) and the cell proliferation
rates. The baseline attachment additionally serves as a
quality control that live cells are being applied to the assay
vessel before any other assay steps are performed.
Cell seeding density is a critical factor in establishing a
useful dynamic range for CI values that encompass the
spectrum of attachment values observed using different
cell lines. The results indicated that 12,500 to 15,000
cells per well in a 96-well format sensor plate is the ideal
seeding density, allowing cell-cell contacts that are
required for authentic epithelial cell signaling. No
significantly proportional increase in CI values was seen
when higher densities of cells (>15,000 cells per well)




Fig. 1 Representative CI versus time-course curves for basic cell attachment. Human breast cancer BT474 cells (a) or R56 patient-derived primary
breast tumor cells (b) were seeded in a sensor plate and allowed to adhere, spread, and proliferate. Impedance was recorded as Cell Index (CI)
versus time for 100 h after seeding. Cell attachment, stabilization, proliferation, and confluent phases are shown as indicated. c Representative
images captured by an inverted phase contrast microscope (magnification: X40) showing cell morphology of BT474 and breast cancer R56
primary cells. Scale bar, 100 μm
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well provided a balance between signal magnitude and
cell conservation when considering data from numerous
breast cancer cell lines and primary cells.
Pathway signaling measurement by the CELx HSF test
SKBr3 HER2+ breast cancer cells in different wells of
the 96-well biosensor were stimulated with EGF or
NRG1b. Representative dose–response curves for EGF
or NRG1b stimulation of SKBr3 HER2+ breast cancer
cells are shown in Fig. 2. EGF and NRG1b activated the
HER2 pathway by initially increasing the impedance
values in a ligand concentration-dependent manner. The
measured EC50 for EGF is 74.1 pM (Fig. 2a), with a 95%
confidence range 62.08–88.44 pM. The measured EC50
for NRG1 is 114.7 pM (Fig. 2b), with a 95% confidence
range 93.30–141.1 pM. In addition, both EGF and
NRG1b signals peaked at stimulus dose of 400 pM to
800 pM. This peak dose range was also seen in other
breast cancer cell lines.
Pathway specificity and selectivity
To address whether pertuzumab and lapatinib have ef-
fects on the cells apart from inhibiting ligand-dependent
HER2 activities, SKBr3 cells were pretreated with pertu-
zumab (10 μg/mL), lapatinib (200nM), or vehicle (con-
trol buffer) 18 h prior to stimulation with growth factors
(NRG1 or EGR). As shown in Fig. 3a, during the 18-h
drug treatment period (time points from drug addition
to GF addition), there was no apparent difference in
CELx test curves between untreated cells (control media
only) and cells treated with pertuzumab or lapatinib. In
contrast, both drugs exhibited significantly inhibitory ef-
fects on HER2 ligand (NRG1)-induced HER2 activities
(see Fig. 3a, time points after GF addition). Dose–re-
sponse curves are shown for lapatinib and pertuzumab
inhibition with EGF and NRG1b stimulation, respect-
ively, in SKBr3 cells (Fig. 3b and c). Lapatinib inhibited
both EGF- and NRG1b-driven HER2 signals to the same
level in SKBr3 (IC50 = 97nM for EGF-driven signal and
IC50 = 175nM for NRG1b-driven signal) (Fig. 3b). In
contrast, pertuzumab showed partial inhibition of both
NRG1 and EGF with significantly higher levels of
inhibition on NRG1b-driven signal than it did on
EGF-driven signal (Fig. 3c). The measured IC50 for
pertuzumab on NRG1 in SKBr3 is 13.94 μg/mL
(Fig. 3b), with a 95% confidence range 9.21–21.02 μg/
mL. Together, these findings demonstrated that the
CI values measured indeed resulted from changes in
the status of NRG1b- and EGF-elicited HER2 sig-
naling activities. In most cell lines tested herein, a
lapatinib concentration of 200nM showed the greatest
inhibitory effect in sensitive cell lines while
a
b
Fig. 2 Dose–response curves of EGF and NRG1b stimulation of HER2 signaling in SKBr3 cells. SKBr3 cells were seeded in the sensor plates and
stimulated with serial titrations of a EGF (0 pM to 1200 pM) or b NRG1b (0 pM to 1350 pM). Instrument data for CELx curves are displayed using
Delta CI values to demonstrate the relative signals to the time point (arrow) when the stimulus (EGF or NRG1b) was added. Log plots of dose-
response curves with error bars of EGF and NRG1b stimulation are shown in the insets for a and b, respectively
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differentiating less sensitive cell samples. Pertuzumab
was initially tested at a range of concentrations to de-
termine the most effective concentration and then
employed at a single maximal dose of 10 μg/mL for
the remainder of the cell samples. Thus, 200nM of
lapatinib and 10 μg/mL of pertuzumab were chosen
as the doses to be used in these experiments.
A panel of pharmacological inhibitors that specifically
inhibit different points in the PI3K and MAPK pathways
was tested in order to determine which pathway(s) was
critically involved in NRG1b- and EGF-directed HER2
signals in breast cancer and thereby specific cellular re-
sponses in our CELx HSF tests.
Dose–response curves of inhibitory effects of
GSK1059615, a selective PI3K inhibitor [28], on ligand-
driven HER2 signals were obtained in SKBr3 cells
(Fig. 4a-b). These data demonstrated that inhibition of
PI3K significantly reduced both EGF- and NRG1b-
directed HER2 signals detected by CELx HSF tests in a
drug dose-dependent manner. Similar results were ob-
tained in other cell lines and with GDC-0941 [29], an-
other selective inhibitor of PI3K (Additional file 2:
Figure S1).
Trametinib, a specific inhibitor of MEK1/2, was also
tested for the effect on inhibition of the MEK/ERK
pathway on ligand-driven HER2 signals [30]. The results
indicated that trametinib did not appear to have an in-
hibitory effect on either EGF- or NRG1b-driven HER2 sig-
nals or attenuate the impedance signal (Additional file 3:
Figure S2) for these cell lines. Inhibition of the p38 MAPK
pathway by doramapimod [31] (Additional file 4:
Figure S3) or inhibition of the JNK pathway by
SP600125 [32] (Additional file 5: Figure S4) had no




Fig. 3 Dose–response curves showing the effects of HER2 inhibitors on EGF- and NRG1b-directed HER2 signaling. a Neither pertuzumab nor
lapatinib has significant effect on baseline cell signal determined before agonist addition. SKBr3 cells were seeded in sensor plates and treated
with pertuzumab (10 μg/mL), lapatinib (200nM), or vehicle (control) 18 h prior to stimulation with NRG1 or EGF. CELx curves are displayed using
Delta CI values to easily compare the relative change in signals from the time point of drug addition. The time points for drug addition and
growth factor (GF) addition are indicated by black arrows. b and c SKBr3 cells were seeded in sensor plates and treated with serial titrations of
lapatinib (0 nM to 3200 nM) or pertuzumab (0 μg/mL to 40 μg/mL) two hours prior to stimulation with EGF or NRG1b. Dose–response curves of
drug inhibition on NRG1b and EGF-driven cell index signals are displayed
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the CELx HSF tests. Similar to what was observed
with the MEK/ERK pathway inhibitor, the results with
these inhibitors suggested that neither of these
MAPK-associated pathways significantly contributed
to the ligand-driven HER2 signaling activities detected
in our CELx HSF tests of breast cancer cells.
Cross-functional receptor specificity
Growth factor receptor / receptor tyrosine kinase (RTK)
signaling networks share many common features, such as
interactions among ligands, antagonists (receptor
inhibitors), and RTKs, receptor phosphorylation / activa-
tion, and activation of downstream pathways. All these
factors could contribute to the CELx signals. Verification
of the specificity and selectivity of the CELx HSF test was
performed by evaluating whether the test response identi-
fies solely HER2-related activity when HER family ligands
are applied to the test cells. Additionally, testing was per-
formed to determine whether the activity of antagonists at
HER family receptors affects growth factor activity on
other receptors and whether antagonists applied to other
receptors affected growth factor activity on HER family re-
ceptors during the test. For an example of evaluating
CELx for receptor cross-talk, the network profile of HER2
signaling was compared with that of insulin-like growth
factor 1 receptor (IGF-1R) by utilizing specific agonists
and antagonists for IGF-1R in the CELx assays. Using the
T47D breast cancer cell line, IGF-1 induced substantial
CELx signals through IGF-1R with an average Delta CI of
0.4 (Fig. 5, right panels). Comparing the magnitude of
IGF-1/IGF-1R signals, NRG1b- and EGF-induced HER2
signals were much larger in these cells (Delta CI = 0.8 to
1.2; Fig. 5, left and middle panels). As expected, both per-
tuzumab and lapatinib significantly inhibited EGF- and
NRG1b-driven HER2-related signals and had no effect on
IGF-1–driven IGF-1R signals in CELx assays. In further
evidence of the specificity of the test response, the IGF-1R
kinase inhibitor, linsitinib [33], completely inhibited IGF-
1-driven IGF-1R signals, but had no effect on either EGF
or NRG1b-driven HER2 signals (Fig. 5c). As an additional
control, GSK1059615, which specifically inhibits PI3K, the
common effector downstream of two HER receptors and
IGF-1R, significantly blocked all three ligand-receptor bio-
sensor signals (Fig. 5d).
Relating the magnitude of CELx HSF test signals to
abnormal HER2 signaling activities in breast cancer cell
lines
After confirming the selectivity and specificity of the CELx
HSF test, ligand-driven HER2 signals were surveyed in 10
a
b
Fig. 4 The PI3K/AKT pathway significantly contributes to the ligand-driven HER2 signaling activities detected by CELx HSF tests. a and b SKBr3
cells were seeded in sensor plates and then treated with a serial titration of the PI3K/AKT pathway inhibitor GSK1059615 (0 nM to 810 nM) two
hours prior to maximal stimulation with NRG1b (800 pM) (a) or EGF (600 pM) (b). CELx curves are displayed using Delta CI values to demonstrate
the relative signals to the time point (arrow) when the stimulus (EGF or NRG1b) was added. Dose–response curves of GSK1059615
inhibition on NRG1b and EGF-driven HER2 signals are shown in the insets
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human breast cancer cell lines overexpressing HER2
(HER2+) and 10 human breast cancer cell lines expressing
lower or normal levels of HER2 (HER2-) in order to deter-
mine whether CELx HSF test positive (HSF+) and CELx
HSF test negative (HSF-) populations exist among HER2+
and HER2- cell types. These cell lines were chosen based
on HER2 gene expression recorded in public databases
such as the Cancer Cell Line Encyclopedia (CCLE) [34].
Here an analysis is provided for the HER2 protein expres-
sion by fluorescence flow cytometry in all 20 cell lines at
the time when cells were processed for CELx HSF tests.
The flow cytometry dataset on HER2 expression status is
consistent with the CCLE reference data (Additional file 6:
Table S2). Two CCLE-listed HER2+ cell lines, MDA-
MB453 and MDA-MB361, had much lower HER2 expres-
sion (approx. 500 mean fluorescence channel units
(MFC)) than the HER2+ clinical standard control cell line,
SKBr3 (2386 MFC). Consulting the CCLE gene copy
number database for these two cell lines revealed that
MDA-MB453 had normal HER2 gene copy number and
MDA-MB361 had more than 2.2 copies per cell. Another
recent study indicated that MDA-MB361 had amplified
gene copy number and would qualify as a clinical HER2+





Fig. 5 Comparison of EGF–HER2, NRG1b–HER2, and IGF-1–IGF-1R signaling systems in CELx assays. Human breast cancer T47D cells pre-seeded in
sensor plates were treated with (a) pertuzumab (10 μg/mL), (b) lapatinib (200 nM), (c) linsitinib (200 nM), or (d) GSK1059615 (300 nM) two hours
prior to stimulation with NRG1b (800 pM), EGF (600 pM), or IGF-1 (8 nM). CELx curves are displayed using Delta CI values to demonstrate the
relative signals to the time point (arrow) when the stimulus (NRG1b, EGF, or IGF-1) was added. Blue curves, unstimulated cells
(baseline); Green curves, cells stimulated with ligand (NRG1b, EGF, or IGF-1); Red curves, cells stimulated with ligand in the presence of drug
(pertuzumab, lapatinib, linsitinib, or GSK1059615)
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cytometry dataset placed both MDA-MB453 and MDA-
MB361 in a lower range more closely associated with the
HER2– group (Additional file 6: Table S2). Thus, these cell
lines were considered according to their clinical assign-
ment: MDA-MB453 is part of the HER2– group and
MDA-MB361 is a member of the HER2+ group. One
HER2- cell line (MDA-MB-134vi) was excluded from fur-
ther analysis because it did not meet the CELx HSF test
criteria for minimum baseline cell attachment on the im-
pedance biosensor.
The CELx HSF test was used to determine the amount
of HER2 participation in NRG1b- and EGF-driven activ-
ity in the HER2+ (n = 9) and HER2- (n = 10) breast can-
cer cell lines in the presence and absence of
pertuzumab. EGF and NRG1b are both capable of initi-
ating signaling of HER family homodimers and heterodi-
mers without HER2 participation. The antibody
pertuzumab’s mechanism of action for disruption of lig-
and induced signaling is by binding to HER2 and pre-
vention of HER2 dimerization with other HER family
members. When pertuzumab was applied to the differ-
ent cell samples, the results showed different levels of at-
tenuation of EGF and NRG1b signals depending on the
cell line. The variable attenuation by pertuzumab is re-
lated to the amount of HER2 participation in each
growth factor initiated signaling for each of the different
cell samples. Thus pertuzumab is an appropriate tool for
the determination of HER2 participation in signaling ac-
tivity measured by the CELx HSF Test and was used for
subsequent data analyses. Results for ligand-driven
HER2 CELx signals from all HER2+ and HER2– cell
lines are presented in Fig. 6a. In this plot, the sum of
NRG1b- and EGF-driven HER2 signals that can be
inhibited by pertuzumab in the same CELx HSF test was
used to calculate the net CELx HSF test value (an indi-
cator of HER2 signaling activity) for each cell line, as de-
scribed in the Methods. Overall, the average CELx HSF
values were higher in the HER2+ group (mean 224 ± 203
response units, range = −65 to 544) than in the HER2-
group (mean 139 ± 296 response units, range = −61 to
952). However, there were cell lines from both groups,
which produced similar signaling activities in CELx HSF
tests. For example, BT483, a HER2- cell line, had one of
the highest levels of HER2 signaling activity (~1000 re-
sponse units) (Fig. 6a) that was more consistent with the
highest HER2+ group. Conversely, there were HER2+
cell lines, such as AU565, that displayed a very low level
of HER2 signaling and were more similar to the lowest
HER2- group. Based on this dataset, 5 out of 9 (56.6%)
HER2+ cell lines and 1 out of 10 (10%) HER2- cell lines
had high CELx HSF values (>224 response units, the
average of the HER2+ group), which may be considered
indicative of potentially abnormally high HER2 pathway
signaling activity.
As further confirmation of the CELx HSF test results
for AU565 and BT483, their responses to pertuzumab
and lapatinib were evaluated. The evaluation focused on
data for NRG1b-driven signaling with these drugs given




Fig. 6 CELx HSF Test signals in HER2+ and HER2- breast cancer cell
lines. a HER2+ cell lines (n = 9) and HER2- cell lines (n = 10) were
evaluated with the CELx HSF test as described in the Methods. The
sum of NRG1b- and EGF-driven HER2 signals that can be inhibited by
the HER2-specific mAb pertuzumab was approximated as response
units for all cell lines and plotted. b Comparison of NRG1b-driven CELx
signals in AU565, BT483, SKBr3 (HER2+ reference cell line), and
MDA-MB231 (HER2- reference cell line) and sensitivities to
HER2-targeted drugs (pertuzumab, lapatinib, and afatinib). c HER2
expression levels in HER2+ (n = 9) and HER2- cell lines (n = 10)
were determined by fluorescence flow cytometry (mean
fluorescence channel units, MFC) and plotted against the
corresponding HER2 signal determined by CELx HSF test
(response units) for each cell line. No correlation between the
two parameters was observed (P = 0.204, R2 = 0.0929). Empty
circles, HER2- cell lines; Filled circles, HER2+ cell lines. The
locations of BT483, AU565, SKBr3 (HER2+ reference cell line) and
MDA-MB231 (HER2- reference cell line) are indicated
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mechanism in HER2 signaling. NRG1b-driven CELx sig-
nals and sensitivities to these drugs are presented in
Fig. 6b. The HER2+ cell line, AU565, had high a NRG1-
driven signal, but was insensitive to either pertuzumab
or lapatinib. This indicated that despite the high HER2
expression level, HER2 was not involved in the NRG1b-
driven signaling, and thus AU565 cells were not sensitive
to the drug designed to block HER2 activity in the CELx
test. This finding is consistent with the previous finding
that AU565 was insensitive to lapatinib [36]. In contrast,
the HER2- cell line, BT483, which was found to have a
very high NRG1-driven signal, was highly sensitive to per-
tuzumab and treatment resulted in nearly complete CELx
test signal attenuation. This result indicated that HER2
participated greatly in NRG1b-driven signaling, although
HER2 expression is low in BT483. Thus, as expected,
BT483 was also sensitive to lapatinib. The effect of lapati-
nib was reinforced by CELx test signal suppression results
with afatinib (Gilotrif ) [37], an irreversible covalent kinase
inhibitor of all ErbB-family members with intrinsic cata-
lytic activity, including HER1, HER2, and HER4 (Fig. 6b).
Afatinib also inhibits HER3 transphosphorylation.
Collectively, these findings suggest that the CELx HSF
test may be a more sensitive and specific indicator of
HER2 pathway activity than methods currently used
to determine HER2 expression status. Furthermore,
correlation analysis results showed that HER2 protein
expression levels were not significantly correlated with
HER2 signaling amplitudes determined by the CELx
HSF test (Fig. 6c) (P = 0.204, R2 = 0.0929), which further
supports the conclusion that HER2 pathway activity can
be independent of HER2 expression status.
Overall, when comparing the magnitude of HER2 lig-
and driven signaling activities determined by CELx HSF
tests, there existed at least four subtypes of cell lines, in-
cluding HER2+/HSF+ (HER2+ cells having high HER2
signaling activities), HER2+/HSF- (HER2+ cells having
low HER2 signaling activities), HER2-/HSF+ (HER2-
cells having high HER2 signaling activities), and HER2-/
HSF- (HER2- cells having low HER2 signaling activities).
The CELx curves characteristic of each subtype are
shown in Fig. 7.
Application of the CELx HSF test to evaluate dynamic
HER2 signaling function in patient samples ex vivo
Following initial results with well-established reference
cell lines, CELx HSF tests were applied to primary epithe-
lial cells derived from two patients with breast cancer and
one healthy control subject as further proof-of-concept.
Typical flow cytometry results for primary samples in
short-term, zero passage culture confirmed a heteroge-
neous population of myo and luminal epithelial cells and
low stromal cell content (Additional file 7: Figure S5). The
responses from primary cells are presented in Fig. 8 of
NRG1b-driven HER2 CELx signals with and without
pertuzumab. The results show that primary cells from a
HER2– breast cancer patient (R39) displayed an amplified
CELx HSF signal due to HER2 participation that was in
the range of the HER2+ reference cell line SKBr3, whereas
primary cells from another patient with HER2– breast
cancer (R49) and a healthy subject (R62) had CELx
HSF signals similar to the HER2- reference cell line
MDA-MB231. These results demonstrate that the
CELx HSF test can be applied to generate high-
content temporal data reflecting the dynamic status of
HER2 signaling network in patient tumor-derived pri-
mary cells. The test revealed very different HER2
pathway signaling activity in samples R39 and R49
despite both being classified as HER2– based on clin-
ical HER2 expression status.
To further corroborate the findings from the pathway
deconvolution experiments in breast cancer cell lines,
the results with patient-derived breast tumor primary
cells (R54) further demonstrated that fresh patient-
derived cells could produce sufficient signal upon
stimulation, confirming the pathway deconvolution re-
sults in a more physiologic setting (Fig. 9). Consistent
with the test results in breast cancer cell lines, both
EGF and NRG1b-driven HER2 signals from primary
R54 cells were detected by CELx HSF tests and were
dependent on PI3K activation (Fig. 9) but not by
MAPK activation (Additional file 8: Figure S6 demon-
strated with lack of activity of trametinib, inhibitor of
MEK1/2 in MAPK pathway) for this primary pathway
dysfunctional specimen.
Discussion
Accurate determination of HER2 status is critical for op-
timizing use of HER2-targeted therapies and improving
therapeutic outcomes. Existing HER2 tests (either IHC
or FISH) [38] only provide information on HER2 protein
expression or gene amplification and do not provide
data on the functional status of the HER2 protein and
its signaling network. By definition, these tests exclude
HER2- breast cancer patients for treatment with
HER2 targeted therapies who may benefit from them.
This study demonstrates the feasibility of the CELx
HSF test, a label-free impedance-based live cell assay,
which quantifies HER2 functional signaling pathway
activity in response to HER2 agonists and antagonists
in a real-time manner.
Breast cancer cell lines have been widely used as
model systems for studies on breast cancer pathobio-
logy and new therapy development [39–41]. Neve et al.
reported that the recurrent genomic and transcriptional
characteristics of 51 breast cancer cell lines mirror
those of 145 primary breast tumors [39]. The present
study successfully employs HER2+ and HER2- breast
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cancer cell lines in optimization, characterization, and
analytical specificity and sensitivity verification studies
during the course of development of a novel functional
signaling test. This work includes the IHC HER2+ clin-
ical reference 3+ cell line SKBr3. We demonstrate that
breast cancer cell lines and primary cells share many
similarities regarding the phenotypic alterations (cell
adhesion and temporal patterns) in response to HER
family pathway agonists and antagonists when mea-
sured by CELx.
Following the cell line work, three different samples of
primary cells were analyzed to demonstrate the feasibil-
ity of applying the CELx HSF test to clinical specimens.
For the clinical specimen, FACS data first established
that cultured primary cells derived from fresh patient
tumor tissue were of the epithelial type with stromal
content typically 5% or less. Several biomarkers that
define luminal and basal types of epithelial cells were
used [42]. The tumors maintained multiple phenotypi-
cally distinct subsets (see Additional file 7: Figure S5) of
epithelial cells during the culture period.
Defining and measuring receptor function using the CELx
HSF test
Reliability, analytical specificity, sensitivity, and accuracy
are essential prerequisites for the CELx HSF test to be
considered for clinical diagnostic applications. When
performing label-free biosensor-based viable cell assays,
complexity is inherent and caution was exercised to test
whether the signal was limited to a biological response
resulting from a single molecule type binding to a single





Fig. 7 Subtypes of CELx HSF curves. Representative CELx time-course curves representing HER2+/HSF+ (HER2+ cells having high HER2 signaling
activities) (a), HER2+/HSF- (HER2+ cells having low HER2 signaling activities) (b), HER2-/HSF+ (HER2- cells having high HER2 signaling activities) (c),
and HER2-/HSF- (HER2- cells having low HER2 signaling activities) (d) are shown. For display purposes, NRG1b and EGF-driven HER2 CELx signals
are shown in separated panels. CELx curves are displayed using Delta CI values to demonstrate the relative signals to the time point (arrow) when
the stimulus (EGF or NRG1b) was added. Red curves, unstimulated cells (control); Green curves, cells stimulated with ligand (NRG1b or EGF); Blue
curves, cells stimulated with ligand in the presence of drug (pertuzumab)
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this study, a series of experiments were performed to
demonstrate the selectivity and specificity of the assay
for cell lines and primary cells.
FDA-approved HER2 inhibitors that treat HER2-
positive breast cancer in clinical settings were used in
this study to serve three purposes. First, the inhibitors
helped to identify the specificity of the impedance signal
arising from treatment of the cells with growth factors.
Second, the anti-HER2 mAb inhibitors isolated the im-
pedance signal arising solely due to HER2 participation
in the growth factor activation of HER family pathway
signaling. This provides a level of detail regarding the
specificity of the selected reagents by using antagonists
that work most proximal to signal initiation, receptor
dimerization and receptor tyrosine kinase priming,
thereby most effectively defining HER2 participation and
isolating early signaling events before signal branching
takes place. Finally, previous studies suggest differential
sensitivities to the HER2 inhibitors among the cells lines
used here [34]. Thus, the utilization of these HER2
signaling inhibitors would help to define the potential
correlation of CELx signal with drug sensitivity in these
cell lines.
The data for testing baseline effect of pertuzumab or
lapatinib alone on cells (Fig. 3, Panel a) indicate that nei-
ther have significant effect on SKBr3 cells in an HER2
overexpressing cell line. The same results were found
when other HER2-overexpressing cell lines were tested
and this result is in good agreement with published data
indicating these drugs are cytostatic, not cytotoxic, and
only slow cell passage through G1 [43, 44].
Trastuzumab was not selected for evaluation in this
study because its primary mechanism of action, as re-
ported by its manufacturer, is not HER2-driven signaling
inhibition, but instead antibody-dependent cell-mediated
cytotoxicity (ADCC). Any results studying the effect of
trastuzumab on HER2-driven signaling would thus be
confounded by the lack of direct linkage between the
activity we are measuring, HER2 signaling, and trastuzu-
mab’s primary mechanism of action (ADCC). Since the
CELx HSF Test is designed to assess HER2 participation
in HER family signaling, pertuzumab, a known HER2
dimer blocker, was selected instead to confirm the
amount of HER2 participation in HER family signaling
in this assay.
All HER2 CELx signals tested are agonist- and
antagonist-concentration dependent within physiological
doses in the picomolar to nanomolar range. When a
HER2 antagonist (e.g. pertuzumab or lapatinib) is added
with agonist, the cells show a significantly attenuated
delta CI compared to the signal for addition of agonist
only, indicative of a blocked HER2 signaling response.
The work employs carefully selected components that
have known specificity and well characterized affinity at
concentrations that reduce the likelihood of activation of
other pathways from high concentrations of agonists.
EGF and NRG1b are very specific ligands for HER1 and
Fig. 8 Validation of CELx HSF test in patient tissue specimen-derived
primary cells ex vivo. Primary epithelial cells derived from two HER2- (R39
and R49) patients with breast cancer and one healthy control subject
(R62) were subjected to CELx HSF tests. Responses of NRG1b-driven
HER2 CELx signals with and without pertuzumab for these primary cells
are plotted along with those for the HER2+ reference cell line (SKBr3)
and the HER2- reference cell line (MDA-MB231) as bar charts. Black bars,
cells stimulated with NRG1b; Grey bars, cells stimulated with NRG1b in
the presence of pertuzumab. HER2- Patient R39 has approximately 80%
of the NRG1 CELx signal of HER2+ cell line SKBr3
ba
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Fig. 9 The PI3K/AKT pathway significantly contributes to the ligand-driven HER2 signaling activities detected by CELx HSF tests in patient-derived
breast tumor primary cells. Patient R54 breast tumor-derived primary cells (15,000 cells per well) pre-seeded in sensor plates were treated with a serial
titration of GSK1059615 (0 nM to 2700 nM) two hours prior to stimulation with NRG1b (800 pM) (a) or EGF (600 pM) (b). The dose-dependent inhibitory
effect of GSK1059615 on ligand-driven HER2 signals is shown
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HER3 receptors. Multiple literature references cite in
vitro receptor affinity of ~100pM for EGF and NRG1b
[45, 46]. This is in close agreement with the CELx test
data presented here and in line with the concentrations
that have been selected to measure agonism and anta-
gonism in the CELx test.
Further dissection of the information from rich CELx
data suggests sources of NRG1-driven test signal that is
linked to more than just HER2/HER3 heterodimerization.
In the SKBr3, HER2+ cells (Fig. 3), lapatinib was able to
reduce the NRG1 and EGF stimulation signals nearly to
zero while pertuzumab was only able to attain partial
(<50%) attenuation of the NRG1 and EGF-induced signals.
The pertuzumab result indicates that HER2 was only
partly involved as a heterodimer with HER1 and HER3 in
the NRG1 and EGF stimulations and the remaining NRG1
and EGF signal could be indicated primarily for homodi-
mer activity at HER1 and HER3, respectively. The lapati-
nib result on EGF stimulation of HER1 seems to confirm
this. However, the lapatinib result on NRG1 signal cannot
be explained quite as simply because HER3 is reported to
possess only weak kinase activity and thus may be unable
to generate very large signals [47, 48]. This opens the pos-
sibility that HER3 binds NRG1 and heterodimerizes with
HER1 or other receptor tyrosine kinases [49] to activate
and sustain PI3K signaling or that HER3 expression is up-
regulated and its dephosphorylation is stalled; both are
mechanisms that have been described previously [50, 51].
This result highlights the difficulty of making limited
protein time point analyses to determine drug efficacy and
points to the value of a functional activity test such as the
CELx HSF.
Determining pathway involvement
Next, a determination was made that the HER2-associated
downstream signaling pathways controlling the cellular
responses were quantified by the CELx HSF test. A series
of pathway deconvolution experiments were performed
using specific agonists and antagonists of different path-
way members. The MAPK and the PI3K/AKT pathways
are the two major pathways downstream of all HER family
receptors [10]. Ligand binding, receptor phosphorylation,
and receptor-intrinsic kinase activation in normal cells
leads to the propagation of signals that regulate important
cellular processes such as cell adhesion, migration,
proliferation, and survival [10]. The present study focuses
on PI3K and MAPK pathways and dissects the signaling
mechanistically related to the HER2-driven phenotypic
alterations. In both breast cancer cell lines and primary
cancer cells, the data show that PI3K, not MAPK, is the
downstream effector that contributes most significantly to
the ligand-driven HER2 signal in the CELx HSF test for
these cancer cell samples. This finding suggests that HER2
heterodimers, especially HER2/HER3, that form as
determined by the use of a HER2 dimer blocker, are prob-
ably dominant in these types of breast tumors. The find-
ings from the current study are in agreement with the
existing literature, which suggests a high level of PI3K sig-
naling in a subset of breast tumors and that HER2/HER3
is a strong driver of oncogenic HER2 signaling through
PI3K activation in this subset [12–15].
The PI3K pathway is a highly complex signal progres-
sion model even though the pathway is often described in
terms that imply otherwise. Multiple positive and negative
effector proteins and mechanisms of PI3K pathway func-
tion and dysfunction have been demonstrated to attenuate
and direct inhibition of PI3K activity in different patients.
For example, mutations of PI3K combined with copy
number variants or RAS activation and heritable cell-to-
cell variability can affect the efficacy of inhibitors [52–54].
Therefore, it is not unexpected that incomplete response
to PI3K inhibition would be seen in different patients.
GSK1059615 on breast cancer cell lines in vitro inhibits
the phosphorylation of Akt at S473, with an IC50 of 40
nM [55], which translates well to the cellular IC50 potency
we find for the compound’s attenuation of signaling.
The CELx HSF test detects unexpected signaling and
drug sensitivity in a HER2- breast cancer cell line. BT-483
is defined as having a PI3K activating mutation, E542K
[52, 56]. This activating mutation has been reported to act
as a resistance mechanism [57] to HER2 signal inhibitors
in HER2 overexpressed cell lines, which is speculated to
explain the mutation’s correlation with poor prognosis.
Despite having only normal expression levels of HER2
receptor, BT-483 recorded very high levels of NRG1b initi-
ated PI3K initiated activity that was almost completely
inhibited by pertuzumab and lapatinib. In fact, BT-483’s
HER2-driven signaling activity was higher than activity
found in all of the HER2+ cell lines evaluated (Fig. 6). This
finding suggests a more complex role for PI3K mutation
as a resistance mechanism for HER2 signal inhibition.
Other HER2-negative cell lines tested in this study, such
as MCF-7 and MDA-MB-361 also have similar (E545K)
PI3K activating mutations. However, the HER2-driven
signaling test measured in these cell lines was consistent
with normal pathway activity. This suggests that the high
NRG1b initiated PI3K activity in BT-483 cells is not
related solely to this PI3k mutation.
Endpoint cell-based assays provide a one-time “snap-
shot” of a focused biological event (e.g., phosphorylation
of HER2 at a single time point). Although protein or
gene based assays provide incremental information, they
are still classical endpoint assays that reflect only the
relative activity of a limited set of proteins that may be
involved in disease propagation, and the results do not
describe the dynamics or real-time status of the
complete HER2 signaling network in a particular patient.
Given that infinite permutations of circumstances are
Huang et al. BMC Cancer  (2017) 17:199 Page 14 of 18
present and each persons’ genomic or proteomic status
does not yet describe the in vivo nature of that individ-
ual’s disease, a truly functional dynamic analysis may be
more appropriate. Furthermore, allosterism, differential
transient phosphorylation, signaling crosstalk, and a myr-
iad of mechanisms of drug effect may contribute to the
quantitative and qualitative activity of the HER2 signaling
pathway in any particular patient [15, 58, 59]. Mylona et
al. report on opposing effects of multisite phosphorylation
shaping a signaling protein response to activation [60].
They conclude that their “results challenge the common
assumption that multisite modification events act unidir-
ectionally and can only be reversed or limited by antagon-
istic enzymes such as phosphatases.” The Mylona et al.
study brings into doubt what is already suspected about
the utility of correlations built upon single time point, lim-
ited site protein phosphorylation analyses’ for assessment
of pathway function in whole cells. Santarpia et al. review
biomarker studies in breast cancer and conclude: “It is
likely that it is the combined effect of all genomic varia-
tions that drives the clinical behavior of a given cancer
[61]. Furthermore, entirely new classes of oncogenic
events are being discovered in the noncoding areas of the
genome and in noncoding RNA species driven by errors
in RNA editing. In light of this complexity, it is not unex-
pected that, with the exception of HER2 amplification, no
robust molecular predictors of benefit from targeted ther-
apies have been identified.” These factors contribute to
the difficulty in using a protein quantification readout to
comprehensively quantify signaling pathway regulation
that relates drug response and therapeutic outcome pre-
diction [15, 58, 59].
To verify the CELx HSF test concept, HER2+ (n = 9)
and HER2- (n = 10) breast cancer reference cell lines
were chosen. Fluorescence flow cytometry measurement
of HER2 protein expression levels demonstrated HER2
expression data largely consistent with published CCLE
data on HER2 gene copy number in these cell lines [34].
However, the HER2 signal function determined by CELx
HSF tests did not show any correlation with HER2
expression levels in these cell lines. The CCLE database
documents HER2+ cell lines that are not responsive
to HER2-targeted drugs in vitro. Recent retrospective
analyses of previous clinical trials indicated that there
is no significant correlation between HER2 gene copy
number or total HER2 protein and clinical benefit
from trastuzumab [6, 7], although the molecular basis
remains unclear and could be very diverse amongst
patients. The results obtained from the present study
suggest that some HER2+ breast tumors may not
respond to HER2-signal inhibitors because they do
not actually exhibit increased HER2 signaling activity
or functional dependence on HER2 signaling, whereas
some HER2- breast tumors could benefit from HER2-
signal inhibitors because the HER2 pathway is abnor-
mally active in these tumors. Collectively, the present
data strongly suggests that HER2 signaling pathway
dysfunction is the critical prerequisite for determining
whether tumor cells respond to HER2-signal
inhibitors.
The present test seeks to identify HER2-negative
samples that have abnormally overactive HER2 signaling.
Previous work by others have presented results that
describe elevated protein ligands [62] of the HER family
as the most likely cause of the PI3K activation in HER2
negative patients. The CELx test results with exogenous
ligand equally applied to all samples suggest that there
are other more systemic causes besides abundance of
ligand. Other published work proposes elevated HER3
expression in HER2-negative cancers as leading to ab-
normal signaling in HER2 negative patients [8]. Several
authors propose increased expression of HER2 in cancer
stem cells to explain HER2– patient abnormal signaling
or responsiveness to HER2-targeted therapy [63, 64].
The flow cytometry data presented here do not support
any of these receptor overexpression mechanisms.
Taken together, the results in this study demonstrate
that the CELx HSF test is a selective and specific assay for
monitoring the dynamic cellular pathway signaling status
in live cells in response to ligand–receptor interactions
and between receptors and receptor-targeting drugs.
Functional assessment of HER2 signaling in live tumor
cells with the CELx HSF test represents a possible new ap-
proach to diagnosing HER2-driven cancer in individual
patients who have normal HER2 expression levels. It is
envisioned that this test would be deployed in a central
lab, where patient tumor specimens would be delivered
and tested. To be successful, greater than 80–90% of clin-
ical specimens must yield test results. To further develop
this method, analytical validation studies meeting CAP
(College of American Pathologists) and CLIA (Clinical
Laboratory Improvement Amendments) established
guidelines for Laboratory Developed Tests would be re-
quired. Finally, the clinical validity of using HER2-driven
signaling activity as a diagnostic biomarker must be
confirmed in a clinical trial that evaluates whether HER2-
breast cancer patients with abnormal HER2-driven signa-
ling benefit from treatment with HER2 signal inhibitors.
Conclusions
HER2 receptor levels do not correlate with the func-
tional activity measured by the CELx test. The wide
range of HER2-driven signaling levels measured suggests
it may be possible to make a distinction between normal
and abnormal levels of activity. Measurement of HER2
signaling activity in the tumor cells of breast cancer pa-
tients is a feasible approach to explore as a biomarker
with the CELx test to identify HER2-driven cancers not
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currently diagnosable with IHC or genomic techniques.
Analytical validation studies and clinical trials treating
HER2- patients with abnormal HER2-driven signaling
would be required to evaluate the analytical and clinical
validity of using this functional biomarker as a diagnos-
tic test to select patients for treatment with HER2
targeted therapy.
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a serial titration of the JNK pathway inhibitor SP600125 (0 nM to 2700
nM) two hours prior to maximal stimulation with NRG1b (800 pM) (A) or
EGF (600 pM) (B). CELx curves are displayed using Delta CI values to
demonstrate the relative signals to the time point (arrow) when the stimu-
lus (EGF or NRG1b) was added. No SP600125 dose-dependent inhibition on
NRG1b or EGF-driven HER2 signals was detected. (PDF 98 kb)
Additional file 6: Table S2. Comparison of HER2 levels in HER2+ and
HER2- breast cancer cell lines. Data from this study, determined by FACS
and expressed in mean fluorescence channel units (MFC); Data from
CCLE database [34], expressed in Log2.(DOCX 34 kb)
Additional file 7: Figure S5. Fluorescence flow cytometry showing two
epithelial markers that delineate basal epithelial, stromal (fibroblast),
progenitor epithelial, and luminal cells in primary cell R49 from short
term culture. The image shows very few fibroblasts and significant
luminal, basal and some progenitor populations. In contrast, a second
image (right panel) is shown for the combined experimental runs of
SKBr3 (luminal breast cancer reference) and MDA-MB-231 (basal epithelial
breast cancer reference) cell lines demonstrating their more monoclonal
character. (PDF 179 kb)
Additional file 8: Figure S6. The MAPK pathway does not significantly
contribute to the ligand-driven HER2 signaling activities detected by CELx
HSF tests in breast cancer primary cells. Patient R54 breast tumor-derived
primary cells (15,000 cells per well) pre-seeded in sensor plates were
treated with a serial titration of the MEK/ERK pathway inhibitor trametinib
(0 nM to 810 nM) two hours prior to stimulation with NRG1b (800 pM)
(A) or EGF (600 pM) (B). No trametinib dose-dependent inhibition on
NRG1b or EGF-driven HER2 signals was detected when data were
subjected to dose–response inhibitory curve fitting. (PDF 44 kb)
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